Stockscreener 앱 받기
90.43
0.59%
0.53
전일 마감가:
$89.90
열려 있는:
$90.68
하루 거래량:
1.26M
Relative Volume:
2.16
시가총액:
$7.44B
수익:
$51.48M
순이익/손실:
$-315.00M
주가수익비율:
-25.32
EPS:
-3.5708
순현금흐름:
$-244.00M
1주 성능:
+9.00%
1개월 성능:
+13.51%
6개월 성능:
+13.56%
1년 성능:
+94.72%
1일 변동 폭
$89.18
$92.47
1주일 범위
$82.53
$92.47
52주 변동 폭
$36.65
$103.00
Kymera Therapeutics Inc Stock (KYMR) Company Profile
명칭
Kymera Therapeutics Inc
전화
857-285-5314
주소
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
90.43 | 7.44B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-06 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | 재개 | Guggenheim | Buy |
| 2025-10-24 | 재확인 | B. Riley Securities | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-06-03 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-20 | 재개 | Stifel | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Market Perform |
| 2024-12-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-26 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | 개시 | Oppenheimer | Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | 개시 | Truist | Buy |
| 2023-05-05 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | 개시 | Raymond James | Mkt Perform |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-08-03 | 개시 | Goldman | Buy |
| 2022-07-20 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | JP Morgan | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2021-09-30 | 개시 | B. Riley Securities | Neutral |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-09-15 | 개시 | BofA Securities | Neutral |
| 2020-09-15 | 개시 | Cowen | Outperform |
| 2020-09-15 | 개시 | Guggenheim | Buy |
| 2020-09-15 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Kymera Therapeutics Inc 주식(KYMR)의 최신 뉴스
KYMR (NASDAQ: KYMR) Atlas Venture, Bruce Booth report proposed share sales - Stock Titan
KYMR (Nasdaq) affiliates and Bruce Booth report multiple share sales on Form 144 - Stock Titan
Kymera Therapeutics Inc (KYMR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kymera Therapeutics stays on track with KT-621 trials, teases IRF5 data - MSN
Kymera Therapeutics Inc (KYMR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kymera Therapeutics Inc (KYMR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
KYMR (Nasdaq) holders file Form 144 to report April 2026 sales - Stock Titan
KYMR (NASDAQ) insiders and Atlas Venture entities report April 2026 share sales - Stock Titan
KYMR (NASDAQ) Form 144: Holders file to sell 11,741 shares on 06/17/2026 - Stock Titan
KYMR (NASDAQ: KYMR) Rule 144 notice — 66,893 shares; prior 10b5-1 sales listed - Stock Titan
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $120 - Moomoo
Kymera Therapeutics Inc (KYMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kymera Therapeutics Inc (KYMR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kymera Therapeutics Inc (KYMR) Institutional Confidence - TradingKey
Kymera Therapeutics Inc (KYMR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kymera Therapeutics Inc (KYMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kymera Therapeutics Inc (KYMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
(KYMR) Risk Channels and Responsive Allocation - Stock Traders Daily
Maven Securities LTD Takes $1.17 Million Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by First Turn Management LLC - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Eventide Asset Management LLC - MarketBeat
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
Kymera Therapeutics, Inc. $KYMR Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
Kymera presents KT-621 phase 1 data in Japanese adults By Investing.com - Investing.com Australia
Kymera reports positive KT-621 phase 1 Japanese study results - grafa.com
Kymera presents KT-621 phase 1 data in Japanese adults - Investing.com
Beyond Inhibition: Kymera's New Drug Aims to Delete Inflammation's Cause - BriefGlance
Monashee Investment Management LLC Acquires New Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting - Investing News Network
Brookline Capital Markets Increases Price Target for Kymera Therapeutics (KYMR) - Insider Monkey
Assessing Kymera Therapeutics (KYMR) Valuation After Recent Share Price Rebound - Yahoo Finance
KYMR Stock Gains as KT-485 Starts Patient Dosing in HS Study - TradingView
10 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
Kymera’s KT-485 Enters Phase 1 Trial Under $20M Sanofi Deal - The Clinical Trial Vanguard
Kymera Therapeutics COO Resigns, Transition Plan Implemented - The Globe and Mail
Brookline Capital raises Kymera stock price target on lupus drug data By Investing.com - Investing.com Australia
Kymera receives $20m milestone from Sanofi for trial start - Investing.com UK
Kymera’s KT-579 shows promise for SLE treatment - BioWorld News
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration - Investing News Network
Kymera receives $20m milestone from Sanofi for trial start By Investing.com - Investing.com India
Sanofi-led trial of new oral inflammation drug ties to $975M - Stock Titan
Kymera Therapeutics, Inc. $KYMR Position Increased by Capital Research Global Investors - MarketBeat
Kymera Therapeutics (KYMR) Unveils Promising Preclinical Data on KT-579 for Lupus Treatment - GuruFocus
Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations - Investing News Network
Kymera appoints Penny Carlson as SVP of development operations - Investing.com UK
Kymera appoints Penny Carlson as SVP of development operations By Investing.com - Investing.com South Africa
Kymera Therapeutics' Jeremy Chadwick to Retire as COO, Will Remain as Advisor - TradingView
COO Jeremy Chadwick to retire from Kymera Therapeutics (NASDAQ: KYMR) - Stock Titan
New Kymera trials chief steps in as COO Jeremy Chadwick retires - Stock Titan
Brookline Capital raises Kymera stock price target on lupus drug data - Investing.com Nigeria
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses - Investing News Network
Kymera Therapeutics Inc (KYMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):